PriceTargets.com logo

OrthoPediatrics - KIDS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $26.44
  • Forecasted Upside: 13.79%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$23.24 As of 09/15/2026 05:00 PM ET
▲ +0.9 (4.03%)

This chart shows the closing price for KIDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OrthoPediatrics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KIDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KIDS

Analyst Price Target is $26.44
▲ +13.79% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for OrthoPediatrics in the last 3 months. The average price target is $26.44, with a high forecast of $35.00 and a low forecast of $20.00. The average price target represents a 13.79% upside from the last price of $23.24.

This chart shows the closing price for KIDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in OrthoPediatrics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2026
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/14/2026BTIG ResearchReiterated RatingBuy ➝ Buy$29.00
8/20/2026BTIG ResearchBoost TargetBuy ➝ Buy$24.00 ➝ $29.00
8/5/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/5/2026Truist FinancialSet Target$22.00
8/5/2026Piper SandlerReiterated RatingOverweight ➝ Overweight$22.00 ➝ $25.00
8/5/2026Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $35.00
7/17/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/16/2026Truist FinancialBoost TargetHold ➝ Hold$17.00 ➝ $20.00
6/15/2026TD CowenReiterated RatingBuy ➝ Buy
5/1/2026Truist FinancialSet Target$17.00
5/1/2026BTIG ResearchReiterated RatingBuy ➝ Buy$24.00
4/24/2026Canaccord Genuity GroupSet Target$25.00
4/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
3/2/2026Truist FinancialBoost TargetHold ➝ Hold$19.00 ➝ $20.00
2/27/2026BTIG ResearchBoost TargetBuy ➝ Buy$23.00 ➝ $24.00
2/27/2026Needham & Company LLCBoost TargetBuy ➝ Buy$26.00 ➝ $30.00
1/27/2026TD CowenUpgradeStrong-Buy
1/26/2026TD CowenInitiated CoverageBuy$23.00
1/22/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/10/2025Canaccord Genuity GroupInitiated CoverageBuy$24.00
10/29/2025Needham & Company LLCLower TargetBuy ➝ Buy$42.00 ➝ $26.00
10/29/2025BTIG ResearchReiterated RatingBuy ➝ Buy$23.00
10/10/2025Truist FinancialSet Target$18.00
10/10/2025Lake Street CapitalLower TargetBuy ➝ Buy$37.00 ➝ $34.00
10/10/2025BTIG ResearchLower TargetBuy ➝ Buy$39.00 ➝ $23.00
10/10/2025CitigroupReiterated RatingOutperform ➝ Outperform
10/10/2025Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$35.00 ➝ $25.00
10/10/2025Stifel NicolausLower TargetBuy ➝ Buy$32.00 ➝ $20.00
10/10/2025Piper SandlerLower TargetOverweight ➝ Overweight$30.00 ➝ $22.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/8/2025Citizens JmpSet TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $35.00
8/8/2025CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
8/6/2025BTIG ResearchLower TargetBuy ➝ Buy$40.00 ➝ $39.00
7/14/2025BTIG ResearchReiterated RatingBuy ➝ Buy
5/8/2025Piper SandlerLower TargetOverweight ➝ Overweight$40.00 ➝ $30.00
5/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/11/2025Truist FinancialLower TargetHold ➝ Hold$26.00 ➝ $24.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/7/2025Lake Street CapitalInitiated CoverageBuy$37.00
3/5/2025Stifel NicolausLower TargetBuy ➝ Buy$40.00 ➝ $32.00
3/5/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
1/14/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
12/18/2024Truist FinancialLower TargetHold ➝ Hold$28.00 ➝ $25.00
11/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
10/14/2024Truist FinancialLower TargetHold ➝ Hold$34.00 ➝ $28.00
9/13/2024Truist FinancialReiterated RatingHold ➝ Hold$30.00 ➝ $34.00
9/13/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$50.00 ➝ $50.00
9/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
8/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
8/8/2024Truist FinancialReiterated RatingHold ➝ Hold$35.00 ➝ $30.00
7/16/2024Truist FinancialLower TargetHold ➝ Hold$38.00 ➝ $35.00
5/8/2024Truist FinancialBoost TargetHold ➝ Hold$35.00 ➝ $38.00
5/7/2024Needham & Company LLCBoost TargetBuy ➝ Buy$37.00 ➝ $42.00
5/7/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$50.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$37.00
3/7/2024Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$50.00
1/25/2024Truist FinancialDowngradeBuy ➝ Hold$39.00 ➝ $31.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$35.00 ➝ $39.00
12/7/2023Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$60.00 ➝ $50.00
11/8/2023Truist FinancialBoost TargetBuy ➝ Buy$31.00 ➝ $35.00
11/7/2023Needham & Company LLCLower TargetBuy ➝ Buy$55.00 ➝ $37.00
10/3/2023BTIG ResearchLower TargetBuy ➝ Buy$59.00 ➝ $52.00
9/1/2023Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$60.00
8/2/2023Truist FinancialLower TargetBuy ➝ Buy$57.00 ➝ $51.00
8/1/2023Citizens JmpReiterated RatingMarket Outperform ➝ Market Outperform$60.00
8/1/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$55.00
4/17/2023Needham & Company LLCReiterated RatingBuy$51.00
4/17/2023Truist FinancialBoost TargetBuy$53.00 ➝ $57.00
3/1/2023Needham & Company LLCBoost TargetBuy$50.00 ➝ $51.00
1/31/2023Truist FinancialBoost TargetBuy$47.00 ➝ $56.00
1/10/2023Stifel NicolausLower TargetBuy$52.00 ➝ $50.00
11/2/2022Citizens JmpLower TargetMarket Outperform$70.00 ➝ $60.00
11/1/2022Piper SandlerLower Target$58.00 ➝ $52.00
11/1/2022Needham & Company LLCLower TargetBuy$59.00 ➝ $50.00
10/17/2022Truist FinancialLower TargetBuy$66.00 ➝ $52.00
8/9/2022BTIG ResearchBoost Target$62.00
8/5/2022Truist FinancialBoost TargetBuy$51.00 ➝ $66.00
7/22/2022Truist FinancialLower Target$51.00
7/18/2022BTIG ResearchLower TargetBuy$65.00 ➝ $61.00
7/18/2022Stifel NicolausLower Target$57.00 ➝ $50.00
6/1/2022Citizens JmpReiterated RatingBuy$77.00
5/6/2022Truist FinancialLower Target$70.00 ➝ $54.00
5/5/2022Piper SandlerLower Target$80.00 ➝ $55.00
3/3/2022Needham & Company LLCLower TargetBuy$83.00 ➝ $65.00
12/22/2021BTIG ResearchLower TargetBuy$75.00 ➝ $68.00
12/21/2021Truist FinancialLower TargetBuy$78.00 ➝ $75.00
(Data available from 9/15/2021 forward)

News Sentiment Rating

1.40 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 42 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 42 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

OrthoPediatrics logo
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Read More

Today's Range

Now: $23.24
Low: $22.40
High: $23.43

50 Day Range

MA: $22.05
Low: $18.72
High: $26.50

52 Week Range

Now: $23.24
Low: $14.42
High: $26.74

Volume

191,967 shs

Average Volume

174,833 shs

Market Capitalization

$606.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of OrthoPediatrics?

The following Wall Street research analysts have issued stock ratings on OrthoPediatrics in the last year: BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Citizens Jmp, Lake Street Capital, Needham & Company LLC, Piper Sandler, Stifel Nicolaus, TD Cowen, Truist Financial Corporation, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for KIDS.

What is the current price target for OrthoPediatrics?

0 Wall Street analysts have set twelve-month price targets for OrthoPediatrics in the last year. Their average twelve-month price target is $26.44, suggesting a possible upside of 18.4%. Needham & Company LLC has the highest price target set, predicting KIDS will reach $35.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $20.00 for OrthoPediatrics in the next year.
View the latest price targets for KIDS.

What is the current consensus analyst rating for OrthoPediatrics?

OrthoPediatrics currently has 1 sell rating, 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KIDS.

What other companies compete with OrthoPediatrics?

Other companies that are similar to OrthoPediatrics include Establishment Labs, NovoCure, Butterfly Network, LeMaitre Vascular and Inspire Medical Systems. Learn More about companies similar to OrthoPediatrics.

How do I contact OrthoPediatrics' investor relations team?

OrthoPediatrics' physical mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company's listed phone number is (574) 268-6379 and its investor relations email address is [email protected]. The official website for OrthoPediatrics is www.orthopediatrics.com. Learn More about contacing OrthoPediatrics investor relations.